Cyient DLM Limited — PPTs, 20-01-2026: Investor Presentation

Cyient DLM's Q3 FY26 revenue stood at ₹303.3 Cr, down 31.7% YoY, primarily due to a large order completed last year. Normalized EBITDA was ₹30.9 Cr (-14.4% YoY), with a strong 10.2% margin reflecting operational resilience and effective cost management. Normalized PAT came in at ₹13.8 Cr (-18.6% YoY). The company's order backlog expanded to ₹2349.4 Cr, driven by a robust ₹387.1 Cr order intake this quarter.

Strategic focus includes strengthening go-to-market presence, expanding sales teams, and building B2S (Build-to-Specification) capabilities, with revenue realization already underway. Recent wins include two new customers in the Medical and Industrial sectors.

Management highlighted strong YoY growth in Industrial and Med-Tech segments. Despite Defense segment degrowth due to prior year's large order, Aerospace grew 12% YoY. The company is actively pursuing inorganic expansion in Europe and a stronger global Defense business.